Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.63 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.63 |
| ▸ | GRM6 | O15303 | 1/20 | 0.63 |
| ▸ | KMO | O15229 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616010 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL30232038 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL44004 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL8083539 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL8127068 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL6747798 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL6747799 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Dl-Phenylalanine SCHEMBL27765394 | 0.93 | ALPI (0.65) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL13660573 | 0.86 | SLC7A5 (0.59) | GRM8GRM4GRM6SLC7A5ALPI | |
| Tyrosine SCHEMBL27411908 | 0.86 | SLC7A5 (0.65) | GRM8GRM4GRM6KMOSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AMBRX, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12404512-B2 | Method for optimizing antibody expression | AMBRX, INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-3788149-B1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | AMBRX INC (US) | 2025-08-27 | — | — | EP | claimed |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | AMBRX, INC. (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119410679-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| EP-0646596-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1999-05-26 | — | — | EP | claimed |
| EP-0646595-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1998-11-04 | — | — | EP | claimed |
| US-5708137-A | Reagent and method for determining activity of herpes protease | G.D. SEARLE & CO. (US) | 1998-01-13 | — | — | US | claimed |
| US-5623049-A | FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | claimed |
| US-5506115-A | FLUOROGENIC PEPTIDES AS SUBSTRATES FOR ASSAY | G. D. SEARLE & CO. (US) | 1996-04-09 | — | — | US | claimed |
| EP-0700928-A1 | Nucleic acid-binding oligomers for therapy and diagnostics | BAYER AG (DE) | 1996-03-13 | — | — | EP | claimed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | claimed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | GRM8 2434/4885GRM4 517/4885GRM6 2131/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | GRM8 4721/4885GRM4 4678/4885GRM6 4357/4885 |
| US-12377294-B2 | Anti-CD3 antibody folate bioconjugates and their uses | FOLR2, FOLR1, CD2 | GRM8 1703/4885GRM4 1984/4885GRM6 1097/4885 |
| US-12577575-B2 | Methods and compositions for promoting non-natural amino acid-containing protein production | AARS1, NSUN3, UPF1 | GRM8 3353/4885GRM4 4616/4885GRM6 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.